Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety

 
• By Jessica Merrill
  
closed book
Pfizer and Lilly closed the book on tanezumab • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip